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Abstract
Introduction: Cardiovascular diseases constitute a major cause of health problems and death in developed countries across the world. 
The increased value of the index of distribution of red blood cell volume (RDW) may be a prognostic marker in patients diagnosed with 
chronic heart failure (CHF). Hypothyroid patients present higher RDW values compared to healthy controls. Taking into consideration 
that RDW might be affected by both thyroid status and CHF, we decided to determine the effect of concomitant hypothyroidism follow-
ing radioiodine therapy (RIT) and CHF on haematological parameters.
Material and methods: Patients with toxic nodular goitre and heart failure with concomitant anaemia were included. Patients underwent 
treatment with radioiodine before the planned heart transplant or pacemaker implantation (combined ICD/CRT-D). After RIT patients 
were divided into the three subgroups: with overt hypothyroidism (TSH ≥ 10 µIU/mL, Group I), subclinically hypothyroid patients (TSH 
4.3–9.0 µIU/mL, Group II), and with high-normal level of TSH (2.6–4.2 µIU/mL, Group III).
Results: Significant correlation between TSH and RDW was observed (r = 0.46; P < 0.0001) after RIT, whereas no correlation between 
serum TSH levels and TIBC and Fe was observed. In Group I significant correlation between TSH and RDW (r = 0.48; P = 0.002) after 
RIT was observed, whereas in two other subgroups there was no significant correlation.
Conclusions: Subclinical hypothyroidism or high-normal levels of TSH did not affect RDW in a significant manner in the studied popula-
tion. Our results demonstrate that overt hypothyroidism may contribute to deterioration of CHF, as reflected in changes of RDW value. 
(Endokrynol Pol 2018; 69 (3): 235–240)
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Streszczenie
Wstęp: Choroby sercowo-naczyniowe stanowią główną przyczynę problemów zdrowotnych i zgonów w krajach wysoko uprzemysłowio-
nych na całym świecie. Podwyższona wartość rozpiętości rozkładu objętości erytrocytów (RDW) może stanowić marker prognostyczny 
u pacjentów z przewlekłą niewydolnością serca (PNS). Pacjenci z niedoczynnością tarczycy mają wyższe wartości RDW w porównaniu 
z osobami zdrowymi. Biorąc pod uwagę, że RDW może być zmienione zarówno przez stan czynnościowy tarczycy, jak i PNS, autorzy 
niniejszej pracy postanowili ustalić wpływ współistniejącej niedoczynności tarczycy spowodowanej terapią jodem promieniotwórczym 
(RIT) i PNS na parametry hematologiczne.
Materiały i metody: Włączono pacjentów z wolem guzkowym toksycznym, PNS oraz towarzyszącą niedokrwistością. U pacjentów prze-
prowadzono RIT przed planowanym przeszczepieniem serca lub implantacją urządzenia resynchronizującego lub defibrylatora (ICD/ 
/CRT-D). Po RIT pacjentów podzielono na 3 podgrupy: z jawną niedoczynnością tarczycy (TSH ≥ 10 µIU/mL — grupa I), z subkliniczną 
niedoczynnością (TSH 4,3–9,0 µIU/mL — grupa II) oraz z TSH w górnej granicy normy (2,6–4,2 µIU/mL — grupa III).
Wyniki: Zaobserwowano istotną korelację między TSH i RDW (r = 0,46; P < 0,0001) po RIT, podczas gdy nie zaobserwowano kore-
lacji między stężeniem TSH i stężeniem żelaza oraz TIBC. W grupie I zaobserwowano istotną korelację między TSH i RDW (r = 0,48; 
P = 0,002) po RIT, jakkolwiek w dwóch pozostałych podgrupach nie zaobserwowano istotnej korelacji.
Agata Czarnywojtek, MD, PhD, Department of Endocrinology, Metabolism, and Internal Medicine, Poznan University of Medical Sciences; De-
partment of Pharmacology, Poznan University of Medical Sciences, Poland; phone: +48 605 463 322, fax: +48 61 869 1690, e-mail: agata.rat@wp.pl
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Wnioski: Subkliniczna niedoczynność tarczycy, jak i wartości TSH w górnej granicy normy nie wpływały na RDW w sposób istotny w 
grupie badanej. Wyniki wskazują, że jawna niedoczynność tarczycy może przyczynić się do zaostrzenia PNS odzwierciedlonej zmianą 
wartości RDW. (Endokrynol Pol 2018; 69 (3): 235–240)
Słowa kluczowe: RDW, niedoczynność tarczycy, niewydolność serca, terapia jodem promieniotwórczym
Introduction
Cardiovascular diseases constitute a major cause of 
health problems and death in developed countries 
across the world [1, 2]. The overall five-year survival 
rate in heart failure (HF) is approximately 25–28% [3, 4]. 
Results presented in recent publications demonstrate 
that the increased value of the index of distribution of 
red blood cell volume (RDW, red cell distribution width) 
may be a prognostic marker in patients diagnosed with 
heart failure [5], but still the left ventricular ejection 
fraction (LVEF) is considered to have the strongest prog-
nostic value. Moreover, other parameters, e.g. increased 
left ventricular volume, increased left ventricular fill-
ing pressure, restrictive mitral inflow, and pulmonary 
hypertension, may be taken into account [6–8]. As 
compared with 2008, the new 2012 ESC guidelines call 
for RDW to be included as a useful prognostic factor in 
patients with chronic heart failure (CHF) [9].
Recent studies have shown that CHF is often ac-
companied by anaemia, and its occurrence is associated 
with a poor prognosis and increased mortality [10–21]. 
It was also demonstrated that anaemia can occur in as 
much as 50%, or even more patients with CHF, while 
the incidence increases with a higher NYHA functional 
class, age of the patient, and in the case of concomi-
tant renal failure [22–24]. Iron deficiency anaemia ac-
companied by elevated RDW may be associated with 
a number of cardiovascular diseases, i.e. hypertension, 
myocardial infarction, and heart failure [25–28]. In cer-
tain conditions, RDW was found to be a useful param-
eter determining prognosis [29–32]. On the other hand, 
in a euthyroid group RDW was a parameter that was 
demonstrated to be negatively correlated with thyroid 
hormones concentration [33]. Hypothyroid patients pre-
sent higher RDW values compared to healthy controls 
[34]. Concordant findings were presented by Aktas et 
al. [35], who demonstrated that higher RDW value was 
the only haematological index significantly different in 
patients with Hashimoto’s thyroiditis in comparison to 
the control group with no evidence of thyroid disease.
Taking into consideration that RDW might be af-
fected by both thyroid status and CHF, we decided to 
determine the effect of concomitant hypothyroidism 
following radioiodine therapy (RIT) on haematologi-
cal parameters in a group of CHF patients. The aim of 
our study was to assess whether hypothyroidism after 
radioiodine therapy is associated with exacerbation of 
CHF, as reflected by changes in RDW value.
Material and methods
Material
Consecutive patients with a toxic nodular goitre and 
heart failure with concomitant anaemia admitted to the 
Endocrine Department in Poznan were included. They 
were on medications prescribed according to current 
therapeutic guidelines [9]. It is a retrospective study of 
patients treated between January 2014 and May 2015. 
Toxic nodular goitre was diagnosed on the basis of 
suppressed TSH levels measured by sensitive assay, 
elevated serum free thyroid hormone levels, nodules 
on thyroid ultrasound examination, and undetectable 
levels of anti-TSH receptor antibodies. The diagnosis 
of hypothyroidism was based on the following criteria: 
decreased free thyroid hormone levels and elevated 
TSH. Anaemia was defined as haemoglobin (Hgb) 
< 12 g/dL in women and < 13 g/dL in men, according 
to the World Health Organisation (WHO) criteria.
Exclusion criteria were: 
 — significant heart valve dysfunction, recent surgical 
treatment for valvular heart disease; 
 — coronary revascularisation (PCI or CABG) within 
the last three months; 
 — concomitant active neoplastic process; 
 — concomitant active inflammation (e.g. infective 
endocarditis); 
 — end-stage renal disease (ESRD) (eGFR < 15 mL/ 
/min/kg); 
 — liver failure; 
 — advanced anaemia (HGB < 6.5 mmol/L); 
 — blood transfusion.
Treatment protocol and serial evaluation 
The study group consisted of 82 patients (42 males and 
40 females), aged 25–89 years. (mean age 55 ± 15 years) 
with toxic nodular goitre and chronic heart failure due 
to left ventricular systolic dysfunction (LVEF < 45%, 
NYHA functional class ≥ II) with concomitant anaemia. 
Patients underwent treatment with radioiodine before 
the planned heart transplant or pacemaker implanta-
tion (combined ICD/CRT-D). The diagnosis of CHF 
was based on the criteria of the European Society of 
Cardiology [7]. 
All of the patients were assigned to radioiodine 
therapy [22 mCi = 800 MBq] alone. Clinical and labora-
tory assessments were performed at baseline as well as 
twice, one and after six months following radioiodine 
treatment. Clinical evaluations were performed by 
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the same physician. None of the patients received an-
tithyroid drug therapy during and after the follow-up. 
L-thyroxine (50–100 µg/day) was given to patients when 
hypothyroidism occurred.
The patients were divided into the three following 
groups: 
 — group I (G-I) comprised 38 patients (F:M ratio was 
1.4:1) with overt hypothyroidism (TSH ≥ 10 µIU/mL) 
with average age 71 years; 
 — in group II (G-II) there were 24 (F:M ratio 1:1.4) 
subclinically hypothyroid patients (TSH 4.3–9.0 µIU/ 
/mL) with average age 66 years; 
 — group III (G=III) comprised 20 patients (F:M ratio 
1:1.2) with high-normal level of TSH 2.6–4.2 µIU/mL. 
The average age in this group was 64 years (Table I). 
Assays
TSH, RDW (red blood cell distribution width), TIBC 
(Total Iron Binding Capacity), and Fe (iron concentra-
tion) were determined in serum by radioimmunoassay 
(RIA) using an automated system (Cobas Immuno602 
— Roche Diagnostics). The reference ranges for serum 
TSH, RDW, TIBC, and Fe concentrations in our labora-
tory were as follows: TSH: 0.27–4.2 µIU/mL, RDW-CV: 
11.0–16.0%, TIBC 250–400 µg/dL, and Fe 37–145 µg/dL.
Statistical analysis
The calculations were performed using StatSoft Sta-
tistica 12 software package. The level of significance 
was set at α = 0.05. A result was considered statisti-
cally significant when P < α. Continuous variables 
were presented as mean ± SD, whereas in the case 
of categorical variables, n and % were also given. For 
all the variables under scrutiny, the compatibility of 
their distributions with the normal distribution was 
checked (Lilliefors test). To compare variables be-
tween the groups, due to the lack of the compatibility 
with the normal distribution, the Mann-Whitney test 
or the Kruskal-Wallis test were applied. In addition, 
to determine which groups differ from one another, 
the Dunn’s multiple comparisons test was used. To 
assess whether changes in levels of the analysed 
parameters have changed as a result of treatment, 
the t-Student test for dependent samples (in the case 
of compliance with the normal distribution) or the 
Wilcoxon test (in the case of non-normal distribu-
tion) were used. In order to investigate the effect of 
TSH on the RDW levels, Fe, and TIBC, due to the 
incompatibility with the normal distribution, we 
calculated RS (Spearman’s rank-order correlation 
coefficient).
Table I. The comparison of the number of patients, age, and sex distribution as well as laboratory findings in three groups of 
patients with overt (G-I) and subclinical (G-II) hypothyroidism as well as high-normal TSH concentration, evaluated before 
and after radioiodine therapy
Tabela I. Porównanie liczby pacjentów, rozkładu wieku i płci, jak również wyników badań laboratoryjnych w trzech grupach 
pacjentów z jawną (G-I) i subkliniczną (G-II) nadczynnością tarczycy, oraz wysokiego normalnego stężenia TSH, oceniane 
przed i po terapii radiojodem
G-I G-II G-III G-I vs G-II 
(P-values)
G-I vs G-III 
(P-values)
G-II vs G-III 
(P-values)
Before radioiodine therapy
Total no. of patients 38 24 20 NS NS NS
No. of F:M 21:17 10:14 9:11 NS NS NS
Age (years) 71 66 64 NS NS NS
TSH [µIU/mL] range: 0.27–4.2 0.1 ± 0.21a 0.0 ± 0.01b 0.0 ± 0.01c NS NS NS
RDW-CV (%) range: 11.0–16.0 16.9 ± 0.62a 16.6 ± 0.62b 16.7 ± 0.62c NS NS NS
TIBC [µg/dL] range: 250–400 363.1 ± 48.03a 384.3 ± 49.43b 378.0 ± 48.23c NS NS NS
Fe [µg/dL] range: 37–145 28.8 ± 5.34a 28.5 ± 5.64b 29.6 ± 3.94c NS NS NS
After radioiodine therapy
TSH [µIU/mL] range: 0.27–4.2 18.6 ± 16.41a 6.8 ± 1.31b 3.2 ± 0.81c < 0.001 < 0.001 0.006
RDW-CV (%) range: 11,0–16,0 17.6 ± 0.82a 17.0 ± 0.52b 16.9 ± 0.62c 0.02 0.003 NS
TIBC [µg/dL] range: 250–400 365.2 ± 52.23a 388.2 ± 45.43b 348.1 ± 47.43c NS NS NS
Fe [µg/dL] range: 37–145 28.5 ± 4.54a 29.7 ± 5.34b 29.7 ± 3.94c NS NS NS
2aP = 0.0001, 2bP = 0.004, 2cP = NS
3aP = NS, 3bP < 0.0001, 3cP = NS
4aP < NS, 4bP < 0.0001, 4cP < 0.0001
Data are given as mean ± S.D. The reference ranges for serum TSH and other parameters in our laboratory were as follows: TSH: 0.27–4.2 µIU/mL, RDW-CV (red blood 
cell distribution width — coefficient of variation): 11.0–16.0%, TIBC (Total Iron Binding Capacity) 250–400 µg/dL, Fe (iron concentration) 37–145 µg/dL.
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Results
A comparison of the levels of all the parameters between 
female and male patients (P = 0.24; Mann-Whitney test) 
did not report any significant differences.
Before RIT, no significant relationships between 
serum TSH levels and RDW (r = –0.06; P = 0.55), TSH 
and TIBC (r = 0.05; P = 0.62), and Fe (r = –0.17; P = 
0.12) were observed.
A significant correlation between TSH and RDW 
was observed (r = 0.46; P < 0.0001) after RIT, whereas 
no correlation between serum TSH levels and TIBC 
(r = –1.69; P = 0.09), and Fe (r = –1.2; P = 0.23) was 
observed.
Relationships between TSH, RDW, and Fe in all 
analysed subgroups (I, II, III).
Group I
In Group I, with high level of serum TSH, a significant 
correlation between TSH and RDW (r = 0.48; P = 0.002) 
after RIT (Fig. 2) was observed. Before RIT, no correla-
tion between TSH and TIBC was observed (r = 0.17; 
P = 0.9), as well as TSH and Fe (r = –0.09; P = 0.58) was 
found. Similarly, after RIT there were no relationships 
between TSH and TIBC (r = –0.13; P = 0.42), or between 
TSH and Fe (r = –0.00; P = 0.99).
Group II
In Group II, before RIT, no correlation between TSH and 
RDW (r = –0.00; P = 0.97), TIBC (r = –0.11; P = 0.59), 
and Fe (r = –0.10; P = 0.61) was observed as well as after 
RIT between TSH and RDW (r = 0.05, P = 0.81), TSH 
and TIBC (r = 0.11; P = 0.59), or TSH and Fe (r = –0.16; 
P = 0.45).
Group III
In Group III, no correlation between TSH and RDW 
was observed (r = –0.13; P = 0.57), TSH and TIBC 
(r = –0.02; P = 0.92) was observed before and after RIT 
— TSH and RDW (r = –0.03, P = 0.87), TSH and TIBC 
(r = 0.13; P = 0.55), TSH and Fe (r = –0.01; P = 0.96). 
A correlation between TSH and Fe (r = –0.45; P = 0.04) 
was observed before RIT.
Discussion
Recent research has proved that anaemia occurs fre-
quently in patients with CHF and it deteriorates the 
prognosis and increases [10–13, 15, 16, 19, 21]. According 
to various studies, anaemia can occur in up to 60% of 
patients with HF, and the probability of its occurrence 
increases with the NYHA failure class, age of the pa-
tient, and especially if there is concomitant renal failure 
[22–24]. Despite the documented relationship between 
anaemia and prognosis in HF, it is still unclear whether 
anaemia is only a reflection of the severity of the disease 
or a concomitant pathological condition that affects 
the deterioration of the prognosis and incidence of 
complications.  
The aetiology of anaemia in HF is multifactorial and 
not fully elucidated [36–39]. Persistent use of aspirin and 
anticoagulants, malnutrition, intestinal malabsorption, 
cardiac cachexia, and renal impairment may adversely 
contribute to its development in patients with HF [24, 40], 
Figure 2. Correlation between TSH and RDW after RIT (r = 
0.48; P = 0.002)
Rycina 2. Współzależność między TSH i RDW po terapii RIT 
(r = 0,48; P = 0.002)
Figure 1. Relationship between TSH levels and RDW in all 
patients
Rycina 1. Związek między stężeniem TSH i RDW u wszystkich 
pacjentów
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as well as persistent therapy with ACE-I/ARB [41, 42]. 
On the other hand, anaemia in the case of thyroid 
dysfunction is caused mainly by the depression of bone 
marrow function due to reduced erythropoietin secre-
tion [33, 43]. The erythropoietin production is further 
decreased in patients with concomitant chronic kidney 
disease [44]. Anaemia in hypothyroidism might also be 
related to iron, folates, or B12 deficiency or accompany-
ing diseases i.e. coeliac disease, pernicious anaemia or 
atrophic gastritis, autoimmune haemolytic syndrome, 
or soft tissue rheumatic disorders [45]. 
In patients with anaemia and HF, elevated levels 
of inflammatory cytokines, such as TNF-alpha and 
IL-6, have been observed [46–48]. These cytokines are 
responsible for blocking iron in the reticuloendothelial 
system (mononuclear phagocyte system) and thus make 
it unavailable for erythropoiesis. It has also been dem-
onstrated that patients with anaemia and HF present 
a similar constellation of parameters of iron metabolism 
to patients with anaemia associated with a chronic 
disease (ACD), i.e. reduced levels of iron, normal or 
reduced levels of TIBC, and elevated levels of ferritin.
In our study we attempted to determine whether 
the thyreometabolic state, particularly hypothyroidism, 
exerts any influence on exacerbation of heart failure. 
To the best of our knowledge, our study is the first to 
demonstrate a significant negative impact of hypo-
thyroidism on haematological parameters in a group 
of patients with CHF. The present study has proven 
that after RIT an increase in TSH level is followed by 
a significant increase in RDW levels in the whole group 
(r = 0.46; P < 0.0001) as well as in subgroup I (Group 
I, r = 0.48; P = 0.002), whereas slightly increased TSH 
levels do not correlate with increased RDW levels 
(Group II and III). The results clearly show that overt 
hypothyroidism (Group I) is accompanied with a great-
er risk of higher RDW being a marker for myocardial 
insufficiency. Therefore, it is important to continuously 
monitor thyroid functional state in these patients to 
prevent development of overt hypothyroidism (TSH > 
10 IU/mL). RDW seems to be a useful, cheap, and easy 
to assay marker; however, it is still an underestimated 
marker in clinical practice.  
A major limitation of our study is the lack of evalua-
tion of BNP and CRP in plasma and an echocardiogram 
necessary to assess the clinical status of the patient, par-
ticularly with respect to heart failure and inflammation 
overlapping with hypothyroidism and anaemia. What 
is more, unfortunately data on RDW values assessed 
in the studied group after euthyroidism is restored 
were not available. However, we might speculate that 
adequate hormonal replacement therapy with L-thy-
roxine brings back the risk in CHF patients to the level 
found in euthyroid subjects with CHF. Hyperthyroid 
patients treated with RIT are at relatively high risk of 
hypothyroidism [49]. However, it should be interpreted 
as neither a complication nor a side effect, but instead 
as an indicator of the efficacy of RIT therapy and the 
desired therapeutic effect. Hypothyroidism following 
RIT can quickly be managed with L-thyroxine, and 
euthyroidism can be promptly restored. However, our 
study demonstrates that high vigilance must be main-
tained when monitoring patients following RIT with 
heart failure because a decline in thyroid hormonal 
production might deteriorate the course of CHF and 
worsen the final prognosis. Thus, it is important for 
practitioners to regularly asses the thyroid function 
following radioiodine administration to prevent devel-
opment of overt hypothyroidism. Subclinical hypothy-
roidism or high-normal levels of TSH seemed not be 
a factor affecting RDW in a significant manner, at least 
in the studied population. In conclusion, our results 
demonstrate that concomitant overt hypothyroidism 
may contribute to deterioration of CHF, as reflected in 
changes of RDW value.
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